93 related articles for article (PubMed ID: 3360092)
1. No effect of oral N-acetylcysteine on the bioavailability of erythromycin and bacampicillin.
Paulsen O; Borgström L; Kågedal B; Walder M
Eur Respir J; 1988 Feb; 1(2):171-5. PubMed ID: 3360092
[TBL] [Abstract][Full Text] [Related]
2. Human pharmacokinetics of erythromycin propionate-N-acetylcysteinate: comparative evaluation with erythromycin stearate and N-acetylcysteine.
De Bernardi M; Feletti F; Gazzani G; Fregnan GB
Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):444-7. PubMed ID: 3198299
[TBL] [Abstract][Full Text] [Related]
3. No effect of omeprazole-induced hypoacidity on the bioavailability of amoxycillin or bacampicillin.
Paulsen O; Höglund P; Walder M
Scand J Infect Dis; 1989; 21(2):219-23. PubMed ID: 2727638
[TBL] [Abstract][Full Text] [Related]
4. Oral bioavailability and in vitro stability of pivampicillin, bacampicillin, talampicillin, and ampicillin in horses.
Ensink JM; Vulto AG; van Miert AS; Tukker JJ; Winkel MB; Fluitman MA
Am J Vet Res; 1996 Jul; 57(7):1021-4. PubMed ID: 8807014
[TBL] [Abstract][Full Text] [Related]
5. [The biological availability of cefadroxil given simultaneously with N-acetylcysteine].
Barkworth MF; Mangold B; Rehm KD; Schmieder G; Töberich H; Vinchenzo A; Weber J; Rübartsch C
Arzneimittelforschung; 1991 Aug; 41(8):839-43. PubMed ID: 1781807
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers.
De Caro L; Ghizzi A; Costa R; Longo A; Ventresca GP; Lodola E
Arzneimittelforschung; 1989 Mar; 39(3):382-6. PubMed ID: 2757663
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin.
Bergan T
Antimicrob Agents Chemother; 1978 Jun; 13(6):971-4. PubMed ID: 677863
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials.
Grandjean EM; Berthet P; Ruffmann R; Leuenberger P
Clin Ther; 2000 Feb; 22(2):209-21. PubMed ID: 10743980
[TBL] [Abstract][Full Text] [Related]
9. Comparative clinical pharmacology of bacampicillin and high oral doses of ampicillin.
Magni L; Sjövall J; Syvälahti E
Infection; 1978; 6(6):283-9. PubMed ID: 730397
[TBL] [Abstract][Full Text] [Related]
10. [Clinical pharmacology of Bacampicillin in comparison to Ampicillin (author's transl)].
Simon C; Malerczyk V; Klaus M
Med Klin; 1978 Jun; 73(24):910-3. PubMed ID: 661733
[TBL] [Abstract][Full Text] [Related]
11. Distribution of radio-labeled N-Acetyl-L-Cysteine in Sprague-Dawley rats and its effect on glutathione metabolism following single and repeat dosing by oral gavage.
Arfsten DP; Johnson EW; Wilfong ER; Jung AE; Bobb AJ
Cutan Ocul Toxicol; 2007; 26(2):113-34. PubMed ID: 17612979
[TBL] [Abstract][Full Text] [Related]
12. Absorption of bacampicillin and ampicillin and penetration into body fluids (skin blister fluid, saliva, tears) in healthy volunteers.
Simon C; Malerczyk V; Klaus M
Scand J Infect Dis Suppl; 1978; (14):228-32. PubMed ID: 279976
[TBL] [Abstract][Full Text] [Related]
13. Rectal bioavailability of bacampicillin hydrochloride in man as determined by reversed-phase liquid chromatography.
Sjövall J; Westerlund D; Alván G; Magni L; Nord CE; Sörstad J
Chemotherapy; 1984; 30(3):137-47. PubMed ID: 6734304
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of bacampicillin in equids.
Sarasola P; McKellar QA
Am J Vet Res; 1995 Nov; 56(11):1486-92. PubMed ID: 8585661
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of bacampicillin compared with those of ampicillin, pivampicillin, and amoxycillin.
Sjövall J; Magni L; Bergan T
Antimicrob Agents Chemother; 1978 Jan; 13(1):90-6. PubMed ID: 626496
[TBL] [Abstract][Full Text] [Related]
16. Human neutrophil oxidative bursts and their in vitro modulation by different N-acetylcysteine concentrations.
Allegra L; Dal Sasso M; Bovio C; Massoni C; Fonti E; Braga PC
Arzneimittelforschung; 2002; 52(9):669-76. PubMed ID: 12404881
[TBL] [Abstract][Full Text] [Related]
17. Increase in glucose consumption by acetylcysteine during hyperglycemic clamp. A study with healthy volunteers.
Ammon HP; Müller PH; Eggstein M; Wintermantel C; Aigner B; Safayhi H; Stützle M; Renn W
Arzneimittelforschung; 1992 May; 42(5):642-5. PubMed ID: 1530678
[TBL] [Abstract][Full Text] [Related]
18. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections.
Blasi F; Page C; Rossolini GM; Pallecchi L; Matera MG; Rogliani P; Cazzola M
Respir Med; 2016 Aug; 117():190-7. PubMed ID: 27492531
[TBL] [Abstract][Full Text] [Related]
19. Modulation of pneumotoxicity by cellular glutathione and precursors.
Cotgreave IA; Grafström RC; Moldéus P
Bull Eur Physiopathol Respir; 1986; 22(1):263s-266s. PubMed ID: 3697545
[TBL] [Abstract][Full Text] [Related]
20. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis.
Rasmussen JB; Glennow C
Eur Respir J; 1988 Apr; 1(4):351-5. PubMed ID: 3294038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
